CIK 0001737953 · Non-accelerated filer<br>Smaller reporting company
Replimune Group, Inc.
Sign in to watch- Ticker
- REPL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Mar 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 822082553
- Phone
- (781) 222-9600
- Business address
- 500 UNICORN PARK, WOBURN, MA, 01801
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $654,036
- in 3 filings
Net −$654,036. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-08-22 | Esposito Pamela Chief Business Officer | Option exercise 10b5-1 | +13,600 | $3.30 | $45K | 277,036 |
| 2023-08-22 | Esposito Pamela Chief Business Officer | Option exercise 10b5-1 | +5,000 | $15.50 | $78K | 282,036 |
| 2023-08-22 | Esposito Pamela Chief Business Officer | Sale 10b5-1 | −18,600 | $20.01 | $372K | 263,436 |
| 2023-08-22 | Esposito Pamela Chief Business Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −13,600 | 91,691 | ||
| 2023-08-22 | Esposito Pamela Chief Business Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −5,000 | 35,750 | ||
| 2023-08-11 | Esposito Pamela Chief Business Officer | Option exercise 10b5-1 | +1,400 | $3.30 | $5K | 264,836 |
| 2023-08-11 | Esposito Pamela Chief Business Officer | Sale 10b5-1 | −1,400 | $20.00 | $28K | 263,436 |
| 2023-08-11 | Esposito Pamela Chief Business Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −1,400 | 105,291 | ||
| 2023-07-10 | Esposito Pamela Chief Business Officer | Option exercise 10b5-1 | +15,000 | $3.30 | $50K | 278,436 |
| 2023-07-10 | Esposito Pamela Chief Business Officer | Option exercise 10b5-1 | +5,000 | $15.50 | $78K | 283,436 |
| 2023-07-10 | Esposito Pamela Chief Business Officer | Sale 10b5-1 | −17,923 | $21.63 | $388K | 265,513 |
| 2023-07-10 | Esposito Pamela Chief Business Officer | Sale 10b5-1 | −2,077 | $21.12 | $44K | 263,436 |
| 2023-07-10 | Esposito Pamela Chief Business Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −15,000 | 106,691 | ||
| 2023-07-10 | Esposito Pamela Chief Business Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −5,000 | 40,750 | ||
| 2023-06-13 | Lewis Tanya Chief Dev. Op. Officer | Sale 10b5-1 | −12,043 | $24.10 | $290K | 136,110 |
| 2023-06-13 | Lewis Tanya Chief Dev. Op. Officer | Sale 10b5-1 | −817 | $23.45 | $19K | 135,293 |
| 2023-06-13 | Patel Sushil Chief Strategy Officer | Sale 10b5-1 | −5,145 | $24.11 | $124K | 149,426 |
| 2023-06-13 | Patel Sushil Chief Strategy Officer | Sale 10b5-1 | −553 | $23.44 | $13K | 148,873 |
| 2023-06-01 | Peeples-Dyer Veleka Director | Grant or award · Employee Stock Option (right to buy) | +50,400 | 50,400 | ||
| 2023-05-16 | Patel Sushil Chief Strategy Officer | Sale | −15,575 | $18.05 | $281K | 154,571 |
Page 7 of 8 · 143 trades